These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9407519)

  • 21. Novel brain targeting prodrugs of naproxen based on dimethylamino group with various linkages.
    Zhang Q; Liang Z; Chen LY; Sun X; Gong T; Zhang ZR
    Arzneimittelforschung; 2012 Jun; 62(6):261-6. PubMed ID: 22407924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.
    Haverdings RF; Haas M; Navis G; Van Loenen-Weemaes AM; Meijer DK; De Zeeuw D; Moolenaar F
    Br J Pharmacol; 2002 Aug; 136(8):1107-16. PubMed ID: 12163343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of low-molecular weight protein (LMWP) lysozyme-curcumin conjugates for kidney drug targeting.
    Wang Y; Sun Y; Wang H; Liu P; Peng W; Duan Y
    J Biomater Sci Polym Ed; 2013; 24(11):1360-7. PubMed ID: 23796036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific drug delivery to the kidney.
    Haas M; Moolenaar F; Meijer DK; de Zeeuw D
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):489-96. PubMed ID: 12766381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.
    Prakash J; de Borst MH; van Loenen-Weemaes AM; Lacombe M; Opdam F; van Goor H; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
    Pharm Res; 2008 Oct; 25(10):2427-39. PubMed ID: 18183478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney.
    Nagai J; Katsube T; Murakami T; Takano M
    J Pharm Pharmacol; 2002 Nov; 54(11):1491-6. PubMed ID: 12495551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of naproxen.
    Davies NM; Anderson KE
    Clin Pharmacokinet; 1997 Apr; 32(4):268-93. PubMed ID: 9113437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diacyl glyceryl ester prodrugs for slow release in the skin: synthesis and in vitro degradation and absorption studies for naproxen derivatives.
    Thorsteinsson T; Másson M; Loftsson T; Haraldsson GG; Stefánsson E
    Pharmazie; 1999 Nov; 54(11):831-6. PubMed ID: 10603609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereoselective disposition of naproxen glucuronide in the rat.
    Iwaki M; Bischer A; Nguyen AC; McDonagh AF; Benet LZ
    Drug Metab Dispos; 1995 Oct; 23(10):1099-103. PubMed ID: 8654198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative aspects of the uptake and degradation of lysozyme in the rat kidney in vivo.
    Hysing J; Tolleshaug H
    Biochim Biophys Acta; 1986 Jun; 887(1):42-50. PubMed ID: 3708010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting naproxen coupled to human serum albumin to nonparenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis.
    Albrecht C; Meijer DK; Lebbe C; Sägesser H; Melgert BN; Poelstra K; Reichen J
    Hepatology; 1997 Dec; 26(6):1553-9. PubMed ID: 9397997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme.
    Pan X; Xie F; Xiao D; Zhou X; Xiao J
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal handling of low molecular weight proteins.
    Maack T
    Am J Med; 1975 Jan; 58(1):57-64. PubMed ID: 1090151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal changes associated with naproxen sodium administration in cynomolgus monkeys.
    Leach MW; Frank DW; Berardi MR; Evans EW; Johnson RC; Schuessler DG; Radwanski E; Cartwright ME
    Toxicol Pathol; 1999; 27(3):295-306. PubMed ID: 10356706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible peritubular binding of a cationic protein (lysozyme) to flounder kidney tubules.
    Ottosen PD
    Cell Tissue Res; 1978 Nov; 194(2):207-18. PubMed ID: 728961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of low molecular weight proteins and dextran on renal cathepsin B and L activity.
    Olbricht CJ; Gutjahr E; Cannon JK; Irmler H; Tisher CC
    Kidney Int; 1990 Mar; 37(3):918-26. PubMed ID: 1690311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses.
    Soma LR; Uboh CE; Rudy JA; Perkowski SZ
    Am J Vet Res; 1995 Aug; 56(8):1075-80. PubMed ID: 8533980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide and Low Molecular Weight Proteins Based Kidney Targeted Drug Delivery Systems.
    Xu P; Zhang H; Dang R; Jiang P
    Protein Pept Lett; 2018; 25(6):522-527. PubMed ID: 29848259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.
    Muscará MN; McKnight W; Del Soldato P; Wallace JL
    Life Sci; 1998; 62(15):PL235-40. PubMed ID: 9566780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absorption and distribution of naproxen in rats orally treated with naproxen betainate sodium salt monohydrate. Comparison with naproxen.
    Marzo A; Ripamonti M; Benatti P; Marzo P; Wool C; Cerutti R; Reiner V
    Arzneimittelforschung; 1997 Apr; 47(4):381-4. PubMed ID: 9150857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.